Sawai Receives Approval for Dutasteride Capsules

Oct. 06. 2020

Osaka, Japan - October 5, 2020 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Dutasteride Capsules (the branded product: ZAGALLO®).

Dutasteride Capsules are prescribed for the treatment of male pattern alopecia.

The product approved by MHLW on October 5

Product Name Dutasteride Capsules ZA 0.5 mg [SAWAI]
Generic name Dutasteride
Brand products ZAGALLO® Capsules 0.5 mg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.